- aAPI SCHOLARSHIP FUND: Deadline for application submission this year is May 31, 2014
Feb 21, 2014
- View pictures from aAPI 2013 Annual meeting
Jan 1, 2014
Friday November 15, 2013:http://alabamaapi.org/aAPI-2013-annual-meetingFriday Saturday November 16, 2013: CME & Cruise:http://alabamaapi. ...
- 2013 aAPI Annual Meeting
Nov 15, 2013
Alabama API Annual Meeting 2013 Huntsville, Alabama PROGRAM Friday November 15, 6pm to 11 pm Doubletree Suites 6000 South Memorial Pkwy SW ...
Zetonna Nasal Aerosol in Allergic Rhinitis
Time: 6:30 PM - 8:30 PM
Location: Sitar Indian Cuisine
Address: 420 Jordan Ln NW Huntsville, AL 35805 (256) 536-3360
Hosted By: Sunovion Pharmaceuticals (Bob Godwin) and aAPI
Message: Please register for this program today.
3 WAYS TO REGISTER:
1. RSVP thru the pingg e-mail you received.
2. Contact Shashi Kumar at email@example.com
3. RSVP below.
Shashi Kumar MD
In accordance with the PhRMA code on interactions with healthcare professionals, attendance at this educational program is limited to healthcare professionals. Accordingly, attendance by spouses and guests is not appropriate and associated expenses will not be reimbursed.
ZETONNA® (ciclesonide) Nasal Aerosol is a corticosteroid indicated for the treatment of symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.
IMPORTANT SAFETY INFORMATIONIn clinical studies local nasal effects of epistaxis, ulcerations, and nasal septal perforations were observed with
ZETONNA® (ciclesonide) Nasal Aerosol. In the short-term and long term trials combined, nasal septal perforations were reported in 2 patients of 2335 treated with ZETONNA Nasal Aerosol compared with none of 892 treated with placebo. Both perforations occurred in 2 week SAR trials while none occurred in the longer term trials. In clinical trials with another formulation of ciclesonide, the development of localized infections of the nose or pharynx with Candida albicans has occurred. Corticosteroids can interfere with wound healing.Prior to initiating therapy, examine patients for evidence of septal perforation, erosions, ulceration, nasal surgery, and trauma. Avoid spraying ZETONNA Nasal Aerosol directly onto the nasal septum. Avoid use in patients with recent septal perforation, nasal erosion, nasal ulcers, nasal surgery, or nasal trauma. Monitor patients periodically for signs of adverse reactions on the nasal mucosa. Discontinue ZETONNA Nasal Aerosol if erosions, ulcerations or perforations occur.Nasal and inhaled corticosteroids may result in the development of glaucoma and cataracts. Monitor patients closely with a change in vision or with a history of increased intraocular pressure, glaucoma, or cataracts.ZETONNA Nasal Aerosol is contraindicated in patients with a known hypersensitivity to ciclesonide or any of the ingredients of ZETONNA Nasal Aerosol. Cases of hypersensitivity reactions following administration of ciclesonide with manifestations such as angioedema, with swelling of the lips, tongue and pharynx have been reported.
Amit Chakrabarty, MD, MS, FRCS, FICS
Click here to learn more...